“Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s175. doi:10.25251/skin.7.supp.175.